Filing Flows › Royalty Pharma (RPRX) › Other royalty income and revenues revenue
Royalty Pharma (RPRX) Other royalty income and revenues revenue by quarter
Royalty Pharma's Other royalty income and revenues revenue was $42.5M in Q3 2026 (third quarter 2026), +18% from Q2 2026. Over the last 7 quarters it ranged from $28.2M (Q2 2025) to $42.5M (Q3 2026).
| Quarter | Other royalty income and revenues revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $42.5M | +18% | +39% |
| Q2 2026 | $36.1M | +1% | +28% |
| Q1 2026 | $35.6M | +20% | +24% |
| Q4 2025 | $29.6M | -3% | — |
| Q3 2025 | $30.5M | +8% | — |
| Q2 2025 | $28.2M | -2% | — |
| Q1 2025 | $28.8M | — | — |
Q3 2026 at a glance
Royalty Pharma, Q3 2026: revenue $690M (+13% year over year), operating margin 59.5%, net earnings $145M, operating cash flow $686M. The chart follows the revenue to costs, profit and cash.
Questions
What is Royalty Pharma's Other royalty income and revenues revenue?
Royalty Pharma's Other royalty income and revenues revenue was $42.5M in Q3 2026 (third quarter 2026), +18% from Q2 2026.
How has Royalty Pharma's Other royalty income and revenues revenue changed?
Over the last 7 quarters it ranged from $28.2M (Q2 2025) to $42.5M (Q3 2026).